Monday, November 8, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1405
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)- 8:30AM-10:30AM
-
Abstract Number: 1412
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)- 8:30AM-10:30AM
-
Abstract Number: 1356
Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1336
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1149
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)- 8:30AM-10:30AM
-
Abstract Number: 1183
Efficacy of Rapid Transition of a Musculoskeletal/Rheumatology/Dermatology Course to Online Learning During COVID-19 Pandemic
Professional Education Poster (1170–1195)- 8:30AM-10:30AM
-
Abstract Number: 1014
Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
RA – Animal Models Poster (1014–1021)- 8:30AM-10:30AM
-
Abstract Number: 1020
Enhancing Endothelial Cell Barrier Function via Sphingosine -1 Phosphate Receptor 1 (S1PR1) – a Novel Treatment for Experimental Arthritis
RA – Animal Models Poster (1014–1021)- 8:30AM-10:30AM
-
Abstract Number: 1050
Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)- 8:30AM-10:30AM
-
Abstract Number: 1326
Epidemiology of Comorbidities in an Incident Psoriasis Cohort: A Population-Based Study
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)- 8:30AM-10:30AM
-
Abstract Number: 1027
Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)- 8:30AM-10:30AM
-
Abstract Number: 1170
Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
Professional Education Poster (1170–1195)- 8:30AM-10:30AM
-
Abstract Number: 1048
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)